Article

What's in a Name — FDA Urged Not to Give Biosimilars Unique Names

This week, a coalition of 32 major pharmacies, health insurers, unions and pension plans asked the FDA not to require distinct names for biosimilar medications, arguing that such a move would not compromise patient safety, but could undermine the savings that are expected to be generated as these medicines are introduced into the US health care system.

When a biosimilar version of the Avastin cancer treatment becomes available, what should it be called?

The chemical name is bevacizumab, and this is often used by physicians and pharmacists when they discuss the drug. But whether such generic nomenclatures should also become widely used commercial monikers is the subject of an ongoing controversy among drug makers and their major customers.

And so, this week, a coalition of 32 major pharmacies, health insurers, unions and pension plans asked the FDA not to require distinct names for biosimilar medications, arguing that such a move would not compromise patient safety, but could undermine the savings that are expected to be generated as these medicines are introduced into the US health care system.

Read the full story here: http://on.wsj.com/1mJKrUO

Source: The Wall Street Journal

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
David Awad, PharmD, BCOP
2 experts in this video
2 experts in this video
Coral Omene, MD, PhD, sitting for a vieo interview
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Coral Omene, MD, PhD, sitting for a vieo interview
David Awad, PharmD, BCOP
Screenshot of Coral Omene, MD, PhD
2 experts in this video
2 experts in this video
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo